Estela Puchulu-Campanella

Estela Puchulu-Campanella

Auto-generated profile, based on publicly available information

Estela Puchulu-Campanella

Department of Chemistry, Purdue University, West Lafayette, Indiana, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2011 in Blood
Verified
Journal Article
Open access
PDF file
EFEmanuela Ferru
Emanuela Ferru
KGKatie Giger
Katie Giger
APAntonella Pantaleo
Antonella Pantaleo
ECEstela Campanella
Estela Campanella
JGJesse Grey
Jesse Grey
Philip LowPhilip Low
Philip Low
The cytoplasmic domain of band 3 serves as a center of erythrocyte membrane organization and constitutes the major substrate of erythrocyte tyrosine kinases. Tyrosine phosphorylation of band 3 is induced by several physiologic stimuli, including malaria parasite invasion, cell shrinkage, normal cell aging, and oxidant stress (thalassemias, sickle cell disease, glucose-6-phosphate dehydrogenase deficiency, etc). In an effort to characterize the biologic sequelae of band 3 tyrosine phosphorylation, we looked for changes in the polypeptide's function that accompany its phosphorylation. We report that tyrosine phosphorylation promotes dissociation of band 3 from the spectrin-actin skeleton as evidenced by: (1) a decrease in ankyrin affinity in direct binding studies, (2) an increase in detergent extractability of band 3 from ghosts, (3) a rise in band 3 cross-linkability by bis-sulfosuccinimidyl-suberate, (4) significant changes in erythrocyte morphology, and (5) elevation of the rate of band 3 diffusion in intact cells. Because release of band 3 from its ankyrin and adducin linkages to the cytoskeleton can facilitate changes in multiple membrane properties, tyrosine phosphorylation of band 3 is argued to enable adaptive changes in erythrocyte biology that permit the cell to respond to the above stresses.

1 February 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RZRongbao Zhao
Rongbao Zhao
SMSang Hee Min
Sang Hee Min
YWYanhua Wang
Yanhua Wang
ECEstela Campanella
Estela Campanella
Philip LowPhilip Low
Philip Low
IGI. David Goldman
I. David Goldman
Recently, this laboratory identified a proton-coupled folate transporter (PCFT), with optimal activity at low pH. PCFT is critical to intestinal folate absorption and transport into the central nervous system because there are loss-of-function mutations in this gene in the autosomal recessive disorder, hereditary folate malabsorption. The current study addresses the role PCFT might play in another transport pathway, folate receptor (FR)-mediated endocytosis. FRα cDNA was transfected into novel PCFT+ and PCFT– HeLa sublines. FRα was shown to bind and trap folates in vesicles but with minimal export into the cytosol in PCFT– cells. Cotransfection of FRα and PCFT resulted in enhanced folate transport into cytosol as compared with transfection of FRα alone. Probenecid did not inhibit folate binding to FR, but inhibited PCFT-mediated transport at endosomal pH, and blocked FRα-mediated transport into the cytosol. FRα and PCFT co-localized to the endosomal compartment. These observations (i) indicate that PCFT plays a role in FRα-mediated endocytosis by serving as a route of export of folates from acidified endosomes and (ii) provide a functional role for PCFT in tissues in which it is expressed, such as the choroid plexus, where the extracellular milieu is at neutral pH.

1 January 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EPEstela Puchulu-Campanella
Estela Puchulu-Campanella
HCHaiyan Chu
Haiyan Chu
DADavid J. Anstee
David J. Anstee
JGJacob A. Galan
Jacob A. Galan
WTW. Andy Tao
W. Andy Tao
Philip LowPhilip Low
Philip Low
Glycolytic enzymes (GEs) have been shown to exist in multienzyme complexes on the inner surface of the human erythrocyte membrane. Because no protein other than band 3 has been found to interact with GEs, and because several GEs do not bind band 3, we decided to identify the additional membrane proteins that serve as docking sites for GE on the membrane. For this purpose, a method known as “label transfer” that employs a photoactivatable trifunctional cross-linking reagent to deliver a biotin from a derivatized GE to its binding partner on the membrane was used. Mass spectrometry analysis of membrane proteins that were biotinylated following rebinding and photoactivation of labeled GAPDH, aldolase, lactate dehydrogenase, and pyruvate kinase revealed not only the anticipated binding partner, band 3, but also the association of GEs with specific peptides in α- and β-spectrin, ankyrin, actin, p55, and protein 4.2. More importantly, the labeled GEs were also found to transfer biotin to other GEs in the complex, demonstrating for the first time that GEs also associate with each other in their membrane complexes. Surprisingly, a new GE binding site was repeatedly identified near the junction of the membrane-spanning and cytoplasmic domains of band 3, and this binding site was confirmed by direct binding studies. These results not only identify new components of the membrane-associated GE complexes but also provide molecular details on the specific peptides that form the interfacial contacts within each interaction.

26 September 2012 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
RFRobert S. Franco
Robert S. Franco
MPM. Estela Puchulu‐Campanella
M. Estela Puchulu‐Campanella
LBLatorya A. Barber
Latorya A. Barber
MPMary B. Palascak
Mary B. Palascak
CJClinton H. Joiner
Clinton H. Joiner
RCRobert M. Cohen
Robert M. Cohen
The changes in red blood cells (RBC) as they age and the mechanisms for their eventual removal have been of interest for many years. Proposed age‐related changes include dehydration with increased density and decreased size, increased membrane IgG, loss of membrane phospholipid asymmetry, and decreased activity of KCl cotransport. The biotin RBC label allows unambiguous identification of older cells and exploration of their properties as they age. Autologous normal human RBC were labeled ex vivo and, after reinfusion, compared with unlabeled RBC throughout their lifespan. RBC density increased with age, with most of the change in the first weeks. Near the end of their lifespan, RBC had increased surface IgG. However, there was no evidence for elevated external phosphatidylserine (PS) even though older RBC had significantly lower activity of aminophospholipid translocase (APLT). KCl cotransport activity persisted well past the reticulocyte stage, but eventually decreased as the RBC became older. These studies place limitations on the use of density fractionation for the study of older human RBC, and do not support loss of phospholipid asymmetry as a mechanism for human RBC senescence. However, increased levels of IgG were associated with older RBC, and may contribute to their removal from the circulation. Am. J. Hematol. 2013.

28 October 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SHSuraj U. Hettiarachchi
Suraj U. Hettiarachchi
YLYen-Hsing Li
Yen-Hsing Li
JRJyoti Roy
Jyoti Roy
FZFenghua Zhang
Fenghua Zhang
EPEstela Puchulu-Campanella
Estela Puchulu-Campanella
Philip LowPhilip Low
Philip Low
Inhibition of phosphatidylinositol 3-kinase in lung myofibroblasts reduced symptoms of IPF in rodents and in vitro human samples.

29 June 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
FZFenghua Zhang
Fenghua Zhang
EAEhab A Ayaub
Ehab A Ayaub
BWBingbing Wang
Bingbing Wang
EPEstela Puchulu‐Campanella
Estela Puchulu‐Campanella
YLYen‐Hsing Li
Yen‐Hsing Li
Philip LowPhilip Low
Philip Low
Fibrotic diseases cause organ failure that lead to ~45% of all deaths in the United States. Activated macrophages stimulate fibrosis by secreting cytokines that induce fibroblasts to synthesize collagen and extracellular matrix proteins. Although suppression of macrophage‐derived cytokine production can halt progression of fibrosis, therapeutic agents that prevent release of these cytokines (e.g., TLR7 agonists) have proven too toxic to administer systemically. Based on the expression of folate receptor β solely on activated myeloid cells, we have created a folate‐targeted TLR7 agonist (FA‐TLR7‐54) that selectively accumulates in profibrotic macrophages and suppresses fibrosis‐inducing cytokine production. We demonstrate that FA‐TLR7‐54 reprograms M2‐like fibrosis‐inducing macrophages into fibrosis‐suppressing macrophages, resulting in dramatic declines in profibrotic cytokine release, hydroxyproline biosynthesis, and collagen deposition, with concomitant increases in alveolar airspaces. Although nontargeted TLR7‐54 is lethal at fibrosis‐suppressing doses, FA‐TLR7‐54 halts fibrosis without evidence of toxicity. Taken together, FA‐TLR7‐54 is shown to constitute a novel and potent approach for treating fibrosis without causing dose‐limiting systemic toxicities.